Jacobson Pharma (HKSE:02633) Total Liabilities : HK$1,151 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma Total Liabilities?

Jacobson Pharma's Total Liabilities for the quarter that ended in Sep. 2024 was HK$1,151 Mil.

Jacobson Pharma's quarterly Total Liabilities declined from Sep. 2023 (HK$1,682.14 Mil) to Mar. 2024 (HK$1,090.49 Mil) but then increased from Mar. 2024 (HK$1,090.49 Mil) to Sep. 2024 (HK$1,150.94 Mil).

Jacobson Pharma's annual Total Liabilities increased from Mar. 2022 (HK$1,797.58 Mil) to Mar. 2023 (HK$2,123.98 Mil) but then declined from Mar. 2023 (HK$2,123.98 Mil) to Mar. 2024 (HK$1,090.49 Mil).

Jacobson Pharma Total Liabilities Historical Data

The historical data trend for Jacobson Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma Total Liabilities Chart

Jacobson Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

1,974.11

2,007.04

1,797.58

2,123.98

1,090.49

Jacobson Pharma Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Total Liabilities	Get a 7-Day Free Trial															2,051.77	2,123.98	1,682.14	1,090.49	1,150.94

Jacobson Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Jacobson Pharma's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	372.843	+	(609.707	+	107.944
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,090

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	3486.854	-	2396.36
	=	1,090

Jacobson Pharma's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	516.489	+	(528.22	+	106.233
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,151

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	3606.697	-	2455.755
	=	1,151

Jacobson Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobson Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG

Website

http://www.jacobsonpharma.com

Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.

Executives

Sum Kwong Yip, Derek	2305 Beneficiary of a trust
Lau Wing Hung
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Queenshill Development Limited
Longjin Investments Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines